Bone Marrow Multipotent Mesenchymal Stromal Cells in Patients with Diffuse Large B-Cell Lymphoma
- Авторлар: Fastova E.1, Magomedova A.1, Petinati N.1, Sats N.1, Kapranov N.1, Davydova Y.1, Drize N.1, Kravchenko S.1, Savchenko V.1
-
Мекемелер:
- National Medical Research Center for Hematology, Ministry of Health of the Russian Federation
- Шығарылым: Том 167, № 1 (2019)
- Беттер: 150-153
- Бөлім: Translated from Kletochnye Tekhnologii v Biologii i Meditsine (Cell Technologies in Biology and Medicine)
- URL: https://journals.rcsi.science/0007-4888/article/view/241529
- DOI: https://doi.org/10.1007/s10517-019-04480-6
- ID: 241529
Дәйексөз келтіру
Аннотация
In diffuse large B-cell lymphoma, bone marrow involvement is rarely diagnosed. We compared the properties of bone marrow stromal progenitor cells and the concentration of fibroblast CFU in patients with diffuse large B-cell lymphoma without bone marrow involvement and in healthy donors. It was found that the properties of multipotent mesenchymal stromal cells in patients in the debut of the disease differed considerably from those in healthy donors. In particular, the total cell production in patients was significantly higher than in donors. In multipotent mesenchymal stromal cells of patients, some cell parameters were changes; the mean fluorescence intensity of the adhesion molecule ICAM1 on the cell surface was increased. The mean fluorescence intensity of mesenchymal stromal cell markers (HLA-ABC, CD73 and CD90) was significantly elevated. The relative expression of BMP4, MMP2, FGFR1, and ICAM1 genes in mesenchymal stromal cell was reduced, while the expression of FGFR2 gene was enhanced. Despite the absence of proven involvement of the bone marrow, the properties of mesenchymal stromal cells, the components in the stromal microenvironment niche regulating hemopoiesis are altered in patients with diffuse large B-cell lymphoma.
Авторлар туралы
E. Fastova
National Medical Research Center for Hematology, Ministry of Health of the Russian Federation
Хат алмасуға жауапты Автор.
Email: fastova12@gmail.com
Ресей, Moscow
A. Magomedova
National Medical Research Center for Hematology, Ministry of Health of the Russian Federation
Email: fastova12@gmail.com
Ресей, Moscow
N. Petinati
National Medical Research Center for Hematology, Ministry of Health of the Russian Federation
Email: fastova12@gmail.com
Ресей, Moscow
N. Sats
National Medical Research Center for Hematology, Ministry of Health of the Russian Federation
Email: fastova12@gmail.com
Ресей, Moscow
N. Kapranov
National Medical Research Center for Hematology, Ministry of Health of the Russian Federation
Email: fastova12@gmail.com
Ресей, Moscow
Yu. Davydova
National Medical Research Center for Hematology, Ministry of Health of the Russian Federation
Email: fastova12@gmail.com
Ресей, Moscow
N. Drize
National Medical Research Center for Hematology, Ministry of Health of the Russian Federation
Email: fastova12@gmail.com
Ресей, Moscow
S. Kravchenko
National Medical Research Center for Hematology, Ministry of Health of the Russian Federation
Email: fastova12@gmail.com
Ресей, Moscow
V. Savchenko
National Medical Research Center for Hematology, Ministry of Health of the Russian Federation
Email: fastova12@gmail.com
Ресей, Moscow
![](/img/style/loading.gif)